Danish company Novo Nordisk has announced that from 2027 it will reduce prices in the U.S. for its entire portfolio of semaglutide medications. This includes injectable and oral Wegovy for obesity treatment, as well as injectable Ozempic for type 2 diabetes and its tablet version, Rybelsus.
The reduction applies to the list price — before deductions of discounts, rebates, or concessions — bringing it down to $675 per month. Wegovy will become 50% cheaper, and Ozempic 35% cheaper.
“This is primarily beneficial for patients who have health insurance plans with high deductibles or co-insurance, where their out-of-pocket costs are directly linked to the list price of the drugs,” explained Dave Moore, Executive Vice President for North America Operations at Novo Nordisk.
However, for patients with a fixed copay under their insurance plan, expenses may remain the same. Last year, the Danish company also launched NovoCare Pharmacy, a direct-to-patient channel for those paying in cash and without insurance, allowing them to purchase Wegovy and Ozempic at reduced prices.
